An evaluation of the interactions of antiestrogens with pituitary and striatal dopamine receptors

We have examined the ability of various antiestrogens (AE's) to compete with ³H-spiroperidol for binding to membrane preparations from striatal tissue and anterior pituitary glands of immature female rats in order to determine the affinity of binding of AE's to D-2 dopamine receptors. Scatchard analyses revealed the presence of a single class of high affinity receptor sites in both the striatum and pituitary with a dissociation constant (K_d) of 0.33 nM and 0.40 nM, respectively, for the dopamine antagonist spiroperidol. The AE's tamoxifen, 4-hydroxy-tamoxifen (TAM-OH), CI-628, LY 117018, and a structurally related compound t-butyl-phenoxyethyl diethylamine (BPEA) were all able to compete with spiroperidol for binding to D-2 receptors and demonstrated relative binding affinities of 0.4-0.06% with spiroperidol set at 100% Dopamine displayed a lower affinity, 0.01% Estradiol failed to compete with spiroperidol for D-2 receptor binding while the non-steroidal estrogen diethylstilbestrol (DES) showed very week competition. For the lipophilic AE's, alteration of the level of their non-specific binding greatly affected their relative affinities in these competitive binding assays. The amine side chain on an aromatic ring appears to be a critical structural requirement in allowing the AE's to bind to the dopamine receptor. The relatively low affinity of AE's for the dopamine receptor and the high degree of interaction of AE's with other proteins suggest that only limited occupancy of D-2 receptors by AE's is likely in vivo.